NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
NPM1 mutation
intensive chemotherapy
myelodysplastic syndromes
myeloid neoplasms
stem cell transplant
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
revised:
02
05
2024
received:
18
03
2024
accepted:
14
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
NPM1-mutated (NPM1 The clinicopathologic features of 54 patients with NPM1 NPM1 Overall, NPM1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the University of Texas MD Anderson Cancer Center Support Grant
ID : CA016672
Organisme : the University of Texas MD Anderson MDS/AML Moon Shot
Informations de copyright
© 2024 American Cancer Society.
Références
Sportoletti P, Varasano E, Rossi R, et al. Mouse models of NPM1‐mutated acute myeloid leukemia: biological and clinical implications. Leukemia. 2015;29(2):269‐278. doi:10.1038/leu.2014.257
Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493‐505. doi:10.1038/nrc1885
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2405. doi:10.1182/blood‐2016‐03‐643544
Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874‐885. doi:10.1182/blood‐2006‐07‐012252
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937‐951. doi:10.1182/blood‐2009‐03‐209262
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424‐447. doi:10.1182/blood‐2016‐08‐733196
Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011;135(1):62‐69. doi:10.1309/ajcpei9xu8pybcio
Peng J, Zuo Z, Fu B, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016;96(1):65‐71. doi:10.1111/ejh.12549
Montalban‐Bravo G, Kanagal‐Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3(6):922‐933. doi:10.1182/bloodadvances.2018026989
Forghieri F, Paolini A, Morselli M, et al. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leuk Lymphoma. 2015;56(11):3222‐3226. doi:10.3109/10428194.2015.1026900
Patel SS, Ho C, Ptashkin RN, et al. Clinicopathologic and genetic characterization of nonacute NPM1‐mutated myeloid neoplasms. Blood Adv. 2019;3(9):1540‐1545. doi:10.1182/bloodadvances.2019000090
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703‐1719. doi:10.1038/s41375‐022‐01613‐1
Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200‐1228. doi:10.1182/blood.2022015850
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617‐629. doi:10.1056/nejmoa2012971
Wright MF, Pozdnyakova O, Hasserjian RP, et al. Secondary‐type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1. Am J Hematol. 2022;97(12). doi:10.1002/ajh.26730
Zhao D, Zarif M, Eladl E, et al. NPM1‐mutated AML‐MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary‐type mutations and confers inferior outcome compared to AML with mutated NPM1. Leuk Res. 2022;118:106869. doi:10.1016/j.leukres.2022.106869
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. doi:10.1182/blood.2022016867
Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367‐1376. doi:10.1182/blood‐2014‐11‐610543
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209‐2221. doi:10.1056/nejmoa1516192
Tazi Y, Arango‐Ossa JE, Zhou Y, et al. Unified classification and risk‐stratification in acute myeloid leukemia. Nat Commun. 2022;13(1):4622. doi:10.1038/s41467‐022‐32103‐8
Pan X, Chang Y, Ruan G, et al. Prognostic impact of FLT3‐ITD mutation on NPM1+ acute myeloid leukaemia patients and related molecular mechanisms. Br J Haematol. 2023;203(2):212‐223. doi:10.1111/bjh.18973
El Hussein S, DiNardo CD, Takahashi K, et al. Acquired WT1 mutations contribute to relapse of NPM1‐mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022;57(3):370‐376. doi:10.1038/s41409‐021‐01538‐w
DiNardo CD, Maiti A, Rausch CR, et al. 10‐day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single‐centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724‐e736. doi:10.1016/s2352‐3026(20)30210‐6
Gangat N, Karrar O, Iftikhar M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193‐202. doi:10.1002/ajh.27138
Jimenez‐Chillon C, Othman J, Taussig D, et al. Venetoclax‐based low intensity therapy in molecular failure of NPM1‐mutated AML. Blood Adv. 2024;8(2):343‐352. doi:10.1182/bloodadvances.2023011106
Issa GC, Bidikian A, Venugopal S, et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023;7(6):933‐942. doi:10.1182/bloodadvances.2022008316
Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A‐rearranged or NPM1‐mutant leukaemia. Nature. 2023;615(7954):920‐924. doi:10.1038/s41586‐023‐05812‐3